Other · developed by Insmed
TPIP F2 (also known as INS1009) is an inhaled agent delivered as a capsule-based dry powder formulation.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07102316 | Phase 1 | Healthy Volunteers | Completed | INSM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy Volunteers
Updated Oct 18, 2026. Something wrong or missing? Report it on the INSM page.
See INSM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INSM catalysts and pipeline →